我们前期的研究已经发现T细胞淋巴瘤（cutanous T cell lymphoma, CTCL）患者的代谢组与正常人之间存在着显著性差异。因此，本项目拟运用代谢组学的研究理念，以LC-MS为技术平台，以CTCL患者血浆/清为研究对象，寻找CTCL特异性标志物，目的是绘制其代谢轮廓，建立其早期诊断模型；进一步构建不同免疫表型和预后的区分模型。研究的成果将为CTCL的早期诊断提供证据，并有利于对CTCL的分型和预后的判断。由于代谢组学与基因组学，转录组学和蛋白质组学均属于"组学"技术，它们既自成体系又密切联系，是一个完整的系统。独立组学的研究关注于某个局部体系，容易以偏概全，因此本项目还将尝试组学间的关联研究，把代谢组学研究的数据与我们前期研究的microRNA结果（属转录组学）作比对，以期获得信息之间的呼应和关联，结合临床数据和特点，验证和修正模型，从而获得对疾病更为清晰和全面的认识。

Our previous study has found that there are significant differences between patients metabolomes of cutanous T cell lymphoma(CTCL) with normal person. Therefore,this project plans to use metabolomics research concept, LC-MS as the technology platform, to investigate the specific markers in the plasma（or serum ）of patients with CTCL. The purpose of this project will be drawing metabolic profiling, establish CTCL early diagnosis model. Furthermore, model of patients with different immunological phenotype and prognosis will be constructed. The results will not only provide evidence for the early diagnosis of CTCL, but also distinguish clinical pheno type of CTCL. Due to metabolomics and genomics, transcriptomics and proteomics are "omics" technology, they are not only self-contained but also closely related, as a comprehesive system. The result of independent "omics" studies is less integrated. Considering this point, we will also focus on the correlation between metabonomics and our previous results of microRNA (transcriptomics). Combined with clinical data, verification and correction model, we will have a more clear and comprehensive understanding of the pathogenesis of the disease.